Is RGC above its 150-day moving average?

RGC is currently below its 150-day moving average by 5.15%. The MA150 sits at $24.41.

What is RGC's RSI right now?

RGC's 14-period RSI is 36.6. This is in a neutral zone (30–70).

Is RGC's MACD bullish or bearish?

RGC's MACD histogram reads -0.4023. A negative histogram means short-term momentum is leaning bearish.

How are RGC's technical signals calculated?

Scanance computes RGC's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

RG

Regencell Bioscience Holdings Limited

RGCHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot · Today

Premium

Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →

Financials · Annual

Revenue

Net Income

-$4.3M

+26.7% YoY

EBITDA

-$4.0M

+27.5% YoY

Scan Results

Daily timeframe

DateIndicatorDetails

About Regencell Bioscience Holdings Limited

Part of the healthcare sector, Regencell Bioscience Holdings Limited (RGC) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $11.45B market cap, placing it firmly in the large-cap category. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.

Key stats

Market Cap$11.45B

EPS$-0.01

52W Change+39.6%

ROE-177.7%

Analysis

The balance sheet looks solid with $2.4M in cash comfortably exceeding the $386K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. ROE of -177.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing RGC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links

Company website ↗

Regencell Bioscience Holdings Limited

News & analytics is part of Premium.

Technical readouts are part of Premium.